Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1434647 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $9.78Day +0.51%Mkt cap $578MP/E (FY) 7.2×1Y −9.5%Off 52W high −35.0%Vol (1Y) 64.8%
Daily closing price, split-adjusted to the current basis; 3y shown of 841 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest13.2% of sh out |
| Days to cover5.4d |
| 13F net flow (QoQ)+1.62% |
| Top-10 13F concentration54.7% |
| Next report (est.)2026-08-05 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)7.2× |
| Sales (TTM)$122.3M |
| Earnings (TTM)$124.2M |
| ROE85.7% |
| Net margin78.2% |
| ROIC−55.1% |
| Debt / equity0.40× |
| Sales growth 3Y118.8% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+9.2% |
| 1Y−9.5% |
| 3Y+100.4% |
| Since incept. (ann.)+25.5% |
Total return through 2026-07-29 · series begins 2023-03-15. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)64.8% |
| Ann. volatility (3Y)60.7% |
| Sharpe (1Y)0.17 |
| Sharpe (3Y)0.69 |
| Max drawdown (1Y)−40.4% |
| Max drawdown (3Y)−43.5% |
| Beta (3Y vs SPY)1.53 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 4.5M | $42M | 7.54% | −1.1% |
| Woodline Partners LP | 3.5M | $32M | 5.84% | +0.0% |
| FMR LLC | 3.2M | $30M | 5.43% | +34.2% |
| Nantahala Capital Management, LLC | 2.5M | $24M | 4.27% | +42.3% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.5M | $23M | 4.18% | new |
| STATE STREET CORP | 1.6M | $15M | 2.64% | +5.3% |
| GEODE CAPITAL MANAGEMENT, LLC | 1.4M | $13M | 2.32% | +2.2% |
| AIGH Capital Management LLC | 1.2M | $11M | 2.03% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | $0.60 | — | $36.2M | +77.5% |
| 2025-12-31 | 2026-03-09 | — | — | $34.1M | +183.4% |
| 2025-09-30 | 2025-11-05 | −$0.01 | — | $26.1M | +605.4% |
| 2025-06-30 | 2025-08-12 | $1.21 | — | $25.9M | +481.7% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
